Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice

Ramesh Gujjar, Farah El Mazouni, Karen L. White, John White, Sharon Creason, David M. Shackleford, Xiaoyi Deng, William N. Charman, Ian Bathurst, Jeremy Burrows, David M. Floyd, David Matthews, Frederick S. Buckner, Susan A. Charman, Margaret A. Phillips, Pradipsinh K. Rathod

Research output: Contribution to journalArticle

102 Citations (Scopus)

Abstract

Malaria is one of the leading causes of severe infectious disease worldwide; yet, our ability to maintain effective therapy to combat the illness is continually challenged by the emergence of drug resistance.We previously reported identification of a new class of triazolopyrimidine-based Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitors with antimalarial activity, leading to the discovery of a new lead series and novel target for drug development. Active compounds from the series contained a triazolopyrimidine ring attached to an aromatic group through a bridging nitrogen atom. Herein, we describe systematic efforts to optimize the aromatic functionality with the goal of improving potency and in vivo properties of compounds from the series. These studies led to the identification of two new substituted aniline moieties (4-SF5-Ph and 3,5-Di-F-4- CF 3-Ph), which, when coupled to the triazolopyrimidine ring, showed good plasma exposure and better efficacy in the Plasmodium berghei mouse model of the disease than previously reported compounds from the series.

Original languageEnglish (US)
Pages (from-to)3935-3949
Number of pages15
JournalJournal of Medicinal Chemistry
Volume54
Issue number11
DOIs
StatePublished - Jun 9 2011

Fingerprint

Antimalarials
Plasmodium falciparum
Amines
Plasmodium berghei
Drug Resistance
Malaria
Communicable Diseases
Nitrogen
Pharmaceutical Preparations
Lead
dihydroorotate dehydrogenase
Therapeutics
aniline
F 4

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice. / Gujjar, Ramesh; El Mazouni, Farah; White, Karen L.; White, John; Creason, Sharon; Shackleford, David M.; Deng, Xiaoyi; Charman, William N.; Bathurst, Ian; Burrows, Jeremy; Floyd, David M.; Matthews, David; Buckner, Frederick S.; Charman, Susan A.; Phillips, Margaret A.; Rathod, Pradipsinh K.

In: Journal of Medicinal Chemistry, Vol. 54, No. 11, 09.06.2011, p. 3935-3949.

Research output: Contribution to journalArticle

Gujjar, R, El Mazouni, F, White, KL, White, J, Creason, S, Shackleford, DM, Deng, X, Charman, WN, Bathurst, I, Burrows, J, Floyd, DM, Matthews, D, Buckner, FS, Charman, SA, Phillips, MA & Rathod, PK 2011, 'Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice', Journal of Medicinal Chemistry, vol. 54, no. 11, pp. 3935-3949. https://doi.org/10.1021/jm200265b
Gujjar, Ramesh ; El Mazouni, Farah ; White, Karen L. ; White, John ; Creason, Sharon ; Shackleford, David M. ; Deng, Xiaoyi ; Charman, William N. ; Bathurst, Ian ; Burrows, Jeremy ; Floyd, David M. ; Matthews, David ; Buckner, Frederick S. ; Charman, Susan A. ; Phillips, Margaret A. ; Rathod, Pradipsinh K. / Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice. In: Journal of Medicinal Chemistry. 2011 ; Vol. 54, No. 11. pp. 3935-3949.
@article{d4f4e60dc4dc444d8343c93419ca4a05,
title = "Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice",
abstract = "Malaria is one of the leading causes of severe infectious disease worldwide; yet, our ability to maintain effective therapy to combat the illness is continually challenged by the emergence of drug resistance.We previously reported identification of a new class of triazolopyrimidine-based Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitors with antimalarial activity, leading to the discovery of a new lead series and novel target for drug development. Active compounds from the series contained a triazolopyrimidine ring attached to an aromatic group through a bridging nitrogen atom. Herein, we describe systematic efforts to optimize the aromatic functionality with the goal of improving potency and in vivo properties of compounds from the series. These studies led to the identification of two new substituted aniline moieties (4-SF5-Ph and 3,5-Di-F-4- CF 3-Ph), which, when coupled to the triazolopyrimidine ring, showed good plasma exposure and better efficacy in the Plasmodium berghei mouse model of the disease than previously reported compounds from the series.",
author = "Ramesh Gujjar and {El Mazouni}, Farah and White, {Karen L.} and John White and Sharon Creason and Shackleford, {David M.} and Xiaoyi Deng and Charman, {William N.} and Ian Bathurst and Jeremy Burrows and Floyd, {David M.} and David Matthews and Buckner, {Frederick S.} and Charman, {Susan A.} and Phillips, {Margaret A.} and Rathod, {Pradipsinh K.}",
year = "2011",
month = "6",
day = "9",
doi = "10.1021/jm200265b",
language = "English (US)",
volume = "54",
pages = "3935--3949",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "11",

}

TY - JOUR

T1 - Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice

AU - Gujjar, Ramesh

AU - El Mazouni, Farah

AU - White, Karen L.

AU - White, John

AU - Creason, Sharon

AU - Shackleford, David M.

AU - Deng, Xiaoyi

AU - Charman, William N.

AU - Bathurst, Ian

AU - Burrows, Jeremy

AU - Floyd, David M.

AU - Matthews, David

AU - Buckner, Frederick S.

AU - Charman, Susan A.

AU - Phillips, Margaret A.

AU - Rathod, Pradipsinh K.

PY - 2011/6/9

Y1 - 2011/6/9

N2 - Malaria is one of the leading causes of severe infectious disease worldwide; yet, our ability to maintain effective therapy to combat the illness is continually challenged by the emergence of drug resistance.We previously reported identification of a new class of triazolopyrimidine-based Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitors with antimalarial activity, leading to the discovery of a new lead series and novel target for drug development. Active compounds from the series contained a triazolopyrimidine ring attached to an aromatic group through a bridging nitrogen atom. Herein, we describe systematic efforts to optimize the aromatic functionality with the goal of improving potency and in vivo properties of compounds from the series. These studies led to the identification of two new substituted aniline moieties (4-SF5-Ph and 3,5-Di-F-4- CF 3-Ph), which, when coupled to the triazolopyrimidine ring, showed good plasma exposure and better efficacy in the Plasmodium berghei mouse model of the disease than previously reported compounds from the series.

AB - Malaria is one of the leading causes of severe infectious disease worldwide; yet, our ability to maintain effective therapy to combat the illness is continually challenged by the emergence of drug resistance.We previously reported identification of a new class of triazolopyrimidine-based Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitors with antimalarial activity, leading to the discovery of a new lead series and novel target for drug development. Active compounds from the series contained a triazolopyrimidine ring attached to an aromatic group through a bridging nitrogen atom. Herein, we describe systematic efforts to optimize the aromatic functionality with the goal of improving potency and in vivo properties of compounds from the series. These studies led to the identification of two new substituted aniline moieties (4-SF5-Ph and 3,5-Di-F-4- CF 3-Ph), which, when coupled to the triazolopyrimidine ring, showed good plasma exposure and better efficacy in the Plasmodium berghei mouse model of the disease than previously reported compounds from the series.

UR - http://www.scopus.com/inward/record.url?scp=79958100876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958100876&partnerID=8YFLogxK

U2 - 10.1021/jm200265b

DO - 10.1021/jm200265b

M3 - Article

C2 - 21517059

AN - SCOPUS:79958100876

VL - 54

SP - 3935

EP - 3949

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 11

ER -